Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06949774

INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)

Led by RAND · Updated on 2025-09-11

550

Participants Needed

1

Research Sites

239 weeks

Total Duration

On this page

Sponsors

R

RAND

Lead Sponsor

A

Arizona State University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Low medication adherence when initiating antiretroviral treatment (ART) is a key barrier to HIV virologic suppression, resulting in avoidable cases of drug resistance, death, and viral transmission. Routinized pill-taking can lead to successful long-term ART adherence, and short-term behavioral economics-based supports are a novel way to overcome the limited success of existing routinization interventions. This study proposes to test this combined approach for promoting long-term ART adherence using a Stage III Sequential, Multiple Assignment, Randomized Trial (SMART) design in one of the largest HIV clinics in Uganda to identify the most cost-effective adaptive intervention that if found effective is generalizable to other settings and other chronic diseases.

CONDITIONS

Official Title

INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female clients age 18 and older
  • Started ART at Mildmay or another clinic within the preceding 2 months
  • Able to speak and understand either English or Luganda
  • Have their own cell phone or have consistent access to someone else's phone
  • Willing to receive daily text messages for the 6 months of intervention duration
  • Willing and able to use the WisePill device distributed for adherence verification for the duration of the study
Not Eligible

You will not qualify if you...

  • Not mentally fit to consent
  • Language other than Luganda or English
  • Not willing to consistently use the WisePill device for adherence measurement

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Mildmay Uganda

Kampala, Uganda, 24985

Actively Recruiting

Loading map...

Research Team

Y

Yvonne Karamagi Site Principal Investigator

CONTACT

L

Lillian Lukuse

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here